Litigation Details for ACTELION PHARMACEUTICALS LTD v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)

ACTELION PHARMACEUTICALS LTD v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)

Docket		Date Filed	2018-01-31
Court	District Court, D. New Jersey	Date Terminated	2020-09-22
Cause	15:1126 Patent Infringement	Assigned To	Freda L. Wolfson
Jury Demand	None	Referred To	Lois H. Goodman
Patents	7,094,781
Link to Docket	External link to docket

Details for ACTELION PHARMACEUTICALS LTD v. ZYDUS PHARMACEUTICALS (USA) INC. (D.N.J. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-01-31	1		infringement of United States Patent No. 7,094,781 (“the ’781 patent” or “the patent-in-suit”). This action …781 patent titled, “Sulfamides and Their Use as Endothelin Receptor Antagonists.” The ’781 patent was…expiration of the patent-in-suit, Zydus has infringed one or more claims of the patent-in-suit under 35…expiration of the patent-in-suit, Zydus will infringe one or more claims of the ’781 patent under 35 U.S.C… expiration date of the patent-in-suit, or any later expiration of any patent term extension or exclusivity	External link to document
2020-09-22	169	Judgment - Consent	ii) the term “Licensed Patent” shall mean United States Patent Number 7,094,781; and (iii) the term … Zydus admits that the claims of the Licensed Patent are valid and enforceable with respect to products…reference-listed drug, and that the claims of the Licensed Patent would be infringed by the commercial manufacture…United States prior to expiration of the Licensed Patent. 4. Unless otherwise specifically…assigns, is enjoined from infringing the Licensed Patent, on its own part or through any Affiliate, by	External link to document